| ID | 115625 |
| Author | |
| Keywords | Insulin icodec
Phase II clinical trial
Treating to target in type 2 diabetes (4-T) trial
Insulin glargine
Food and drug administration (FDA)
|
| Content Type |
Journal Article
|
| Description | There was a new report for once-weekly Novo Nordisk's insulin icodec. After subcutaneous injection, the blood concentration reaches its maximum in 16 hours, and the half-life is about 1 week. The phase II clinical trial showed i) subjects were 247 type 2 diabetes, 59.6 ± 8.9 years, BMI 31.3 ± 4.6, HbA1c 8.0 ± 0.7%, FPG 181 ± 42 mg/dL, ii) For 26 weeks, HbA1c improved from 8.1% to 6.7% in group Ico and from 8.0% to 6.9% in group Gla with no significant difference, iii) significantly markers superior to Group Ico included changes in the mean daily glucose profile and time period of 70-140 mg/dL by CGM. Insulin icodec will hopefully develop smooth next phase trial.
|
| Journal Title |
Journal of Diabetes, Obesity & Metabolism
|
| Publisher | Yumed Text
|
| Volume | 3
|
| Issue | 2
|
| Start Page | e105
|
| Published Date | 2020-12-24
|
| Rights | Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License(https://creativecommons.org/licenses/by-nc-sa/4.0/).
|
| URL ( Publisher's Version ) | |
| FullText File | |
| language |
eng
|
| TextVersion |
Publisher
|
| departments |
Medical Sciences
|
